Celldex Rindopepimut vaccine trial yields positive data

Rindopepimut, an immunotherapeutic vaccine, targets the tumour-specific oncogene, epidermal growth factor receptor variant III (EGFRvIII).

The Phase 2 data demonstrated a final median OS of 24.6 months from diagnosis, which is consistent with two previous smaller studies with Rindopepimut in GB (ACTIVATE and ACT II).

In the ACT III 2 study, the two-year survival rate was found to be 52%, which is also similar to the earlier studies that showed 50% survival at two years.

Lead investigator of ACT III study Rose Lai said the study data will support the validity of Rindopepimut in EGFRvIII patient population.